#gsk — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #gsk, aggregated by home.social.
-
GSK to Advance mRNA Influenza Vaccine Into Phase III Development
GSK plc GSK announced that it plans to advance the mRNA-based seasonal influenza (flu) vaccine candidate into late-stage development.…
#EuropeSays #Britain #Europe #EU #GSK #AnikaTherapeutics #AnikaTherapeuticsANIK #GSKPLCSponsoredADR #PLC) #Repligen #RepligenRGEN #Zacks #ZacksInvestmentResearch
https://www.europesays.com/britain/118817/ -
https://www.europesays.com/britain/118817/ GSK to Advance mRNA Influenza Vaccine Into Phase III Development #AnikaTherapeutics #AnikaTherapeuticsANIK #GSK #GSKPLCSponsoredADR #PLC) #Repligen #RepligenRGEN #Zacks #ZacksInvestmentResearch
-
GSK (LSE:GSK), What Is Behind The Latest Attention?
GSK (LSE:GSK) is back in focus after presenting positive phase II data for its mRNA seasonal flu vaccine…
#EuropeSays #Britain #Europe #EU #GSK
https://www.europesays.com/britain/118415/ -
https://www.europesays.com/britain/118415/ GSK (LSE:GSK), What Is Behind The Latest Attention? #GSK
-
https://www.europesays.com/britain/?p=118119 Mobile livescore – Flashscore.mobi football scores #GSK
-
GSK advances mRNA flu vaccine to phase 3 after positive results
(Alliance News) – GSK PLC on Tuesday said a phase 2 probe of its mRNA flu vaccine candidate…
#EuropeSays #Britain #Europe #EU #GSK
https://www.europesays.com/britain/117985/ -
https://www.europesays.com/britain/117985/ GSK advances mRNA flu vaccine to phase 3 after positive results #GSK
-
Hutchmed China inks USD1.30 billion GSK deal for cancer drug HMPL-A830
(Alliance News) – Hutchmed China PLC on Thursday announced that its subsidiary, Hutchmed Ltd, has entered into an…
#EuropeSays #Britain #Europe #EU #GSK
https://www.europesays.com/britain/117974/ -
https://www.europesays.com/britain/117974/ Hutchmed China inks USD1.30 billion GSK deal for cancer drug HMPL-A830 #GSK
-
Can GSK’s Hepatitis B Breakthrough Become a £2 Billion Opportunity?
GSK plc (NYSE:GSK) has reached two important regulatory milestones involving treatments for chronic hepatitis B and rectal cancer.…
#EuropeSays #Britain #Europe #EU #GSK #GSKplc #Jemperli #NYSE
https://www.europesays.com/britain/117964/ -
https://www.europesays.com/britain/117964/ Can GSK’s Hepatitis B Breakthrough Become a £2 Billion Opportunity? #GSK #GSKPlc #Jemperli #NYSE
-
Hesham A. Abdullah Announces a New Oncology Partnership Between GSK and HUTCHMED
Hesham A. Abdullah/LinkedIn Hesham A. Abdullah, Senior Vice President of Global Head Oncology, Research and Development at GSK…
#EuropeSays #Britain #Europe #EU #GSK
https://www.europesays.com/britain/117866/ -
https://www.europesays.com/britain/117866/ Hesham A. Abdullah Announces a New Oncology Partnership Between GSK and HUTCHMED #GSK
-
HUTCHMED Secures $110 Million Licensing Deal with GSK for Promising Solid Tumour Drug, ETPharma
Shanghai: GSK subsidiary GlaxoSmithKline Intellectual Property (No. 4) Ltd will pay a unit of HUTCHMED (China) $110 million…
#EuropeSays #Britain #Europe #EU #GSK #experimentalsolidtumourdrug #GlaxoSmithKline #HMPL-A830 #HUTCHMEDlicensingdeal #solidtumours
https://www.europesays.com/britain/117654/ -
https://www.europesays.com/britain/117654/ HUTCHMED Secures $110 Million Licensing Deal with GSK for Promising Solid Tumour Drug, ETPharma #ExperimentalSolidTumourDrug #GlaxoSmithKline #GSK #HMPLA830 #HUTCHMEDLicensingDeal #SolidTumours
-
GSK advances mRNA flu shot after Phase II success
Drugmaker GSK said on Tuesday that it will move its mRNA seasonal flu vaccine candidate into Phase III…
#EuropeSays #Britain #Europe #EU #GSK #advances #after #Category:All #Category:CompanyNews #Category:MarketPulse #Category:MarketReport #Category:NewsandAnnouncements #Category:Sectorial:HealthTechnology #mRNA #Phase #shot #success
https://www.europesays.com/britain/117636/ -
Hutchmed, GSK Ink $1.3B Cancer Drug Deal
Hutchmed Limited has entered into an exclusive development and license agreement with a subsidiary of GSK plc, giving…
#EuropeSays #Britain #Europe #EU #GSK
https://www.europesays.com/britain/117616/ -
https://www.europesays.com/britain/117616/ Hutchmed, GSK Ink $1.3B Cancer Drug Deal #GSK
-
Is GSK (LSE:GSK) Still Reasonable, Or Is The Value Already Priced In?
GSK stock has delivered a strong 54.4% gain over the past 5 years, yet the current checks still…
#EuropeSays #Britain #Europe #EU #GSK
https://www.europesays.com/britain/117597/ -
https://www.europesays.com/britain/117597/ Is GSK (LSE:GSK) Still Reasonable, Or Is The Value Already Priced In? #GSK
-
GSK (LSE:GSK) Wins First Global Approval For Chronic Hepatitis B Functional Cure
GSK (LSE:GSK) has received the world’s first regulatory approval for Hibsago (bepirovirsen) as a functional cure for chronic…
#EuropeSays #Britain #Europe #EU #GSK
https://www.europesays.com/britain/117584/ -
https://www.europesays.com/britain/117584/ GSK (LSE:GSK) Wins First Global Approval For Chronic Hepatitis B Functional Cure #GSK
-
China’s Hutchmed inks $1.3 B deal with GSK for KRAS-EGFR-antibody conjugate cancer therapy
China’s Hutchmed inks $1.3 B deal with GSK for KRAS-EGFR-antibody conjugate cancer therapy September 4, 2026 | Friday…
#EuropeSays #Britain #Europe #EU #GSK #Cancer #China #EGFR #Hutchmed #KRAS
https://www.europesays.com/britain/117573/ -
HUTCHMED (China) signs licensing deal with GSK for experimental solid tumour drug
Sept 3 (Reuters) – GSK subsidiary GlaxoSmithKline Intellectual Property (No. 4) Ltd will pay a unit of HUTCHMED…
#EuropeSays #Britain #Europe #EU #GSK #Markets
https://www.europesays.com/britain/117557/ -
https://www.europesays.com/britain/117557/ HUTCHMED (China) signs licensing deal with GSK for experimental solid tumour drug #GSK #Markets
-
GSK to Advance mRNA Influenza Vaccine Into Phase III Development
GSK plc GSK announced that it plans to advance the mRNA-based seasonal influenza (flu) vaccine candidate into late-stage development.…
#EuropeSays #Britain #Europe #EU #GSK #AnikaTherapeutics #AnikaTherapeuticsANIK #GSKPLCSponsoredADR #PLC) #Repligen #RepligenRGEN #Zacks #ZacksInvestmentResearch
https://www.europesays.com/britain/117543/ -
https://www.europesays.com/britain/117543/ GSK to Advance mRNA Influenza Vaccine Into Phase III Development #AnikaTherapeutics #AnikaTherapeuticsANIK #GSK #GSKPLCSponsoredADR #PLC) #Repligen #RepligenRGEN #Zacks #ZacksInvestmentResearch
-
GSK’s mRNA flu vaccine data closely tracks Moderna’s, Deutsche Bank says
GSK’s mRNA flu vaccine data closely tracks Moderna’s, Deutsche Bank says Proactive uses images sourced from Shutterstock GSK…
#EuropeSays #Britain #Europe #EU #GSK #deutschebank #Moderna
https://www.europesays.com/britain/117528/ -
https://www.europesays.com/britain/117528/ GSK’s mRNA flu vaccine data closely tracks Moderna’s, Deutsche Bank says #DeutscheBank #GSK #Moderna
-
Is GSK (LSE:GSK) Losing The Room As Vaccine Demand Questions Resurface?
Highlights GSK featured among the sharpest decliners on London’s leading benchmark Vaccine demand patterns remain the most closely…
#EuropeSays #Britain #Europe #EU #GSK #IsGSK(LSE:GSK)LosingTheRoomAsVaccineDemandQuestionsResurface?
https://www.europesays.com/britain/117512/ -
GSK hopes to take on Moderna as it moves mRNA flu vaccine to Phase III trial
GSK’s seasonal, mRNA-based influenza vaccine is progressing to a Phase III study after securing a safety and efficacy…
#EuropeSays #Britain #Europe #EU #GSK #August2025 #august2026 #british #ClinicalTrialsArena #GlobalData #mFlusvia #Moderna #PhaseIII #RFKJr
https://www.europesays.com/britain/115793/ -
https://www.europesays.com/britain/115793/ GSK hopes to take on Moderna as it moves mRNA flu vaccine to Phase III trial #August2025 #August2026 #british #ClinicalTrialsArena #GlobalData #GSK #mFlusvia #Moderna #PhaseIII #RFKJr
-
GSK heads to Cambridge with long-awaited positive vibes | Nils Pratley
By Nils PratleyPharmaceutical company’s move to new £400m research centre accompanied by encouraging news for shareholders
#Pharmaceuticalsindustry #GSK #UKnews #Business #Cambridge #Cambridgeshire #TheGuardian #NilsPratley
-
GSK heads to Cambridge with long-awaited positive vibes | Nils Pratley
By Nils PratleyPharmaceutical company’s move to new £400m research centre accompanied by encouraging news for shareholders
#Pharmaceuticalsindustry #GSK #UKnews #Business #Cambridge #Cambridgeshire #TheGuardian #NilsPratley
-
GSK heads to Cambridge with long-awaited positive vibes | Nils Pratley https://www.theguardian.com/business/nils-pratley-on-finance/2026/jul/28/gsk-cambridge-long-awaited-good-vibes #PharmaceuticalsIndustry #UkNews #Business #Gsk
-
GSK heads to Cambridge with long-awaited positive vibes | Nils Pratley https://www.theguardian.com/business/nils-pratley-on-finance/2026/jul/28/gsk-cambridge-long-awaited-good-vibes #PharmaceuticalsIndustry #UkNews #Business #Gsk
-
GSK heads to Cambridge with long-awaited positive vibes | Nils Pratley https://www.theguardian.com/business/nils-pratley-on-finance/2026/jul/28/gsk-cambridge-long-awaited-good-vibes #PharmaceuticalsIndustry #UkNews #Business #Gsk
-
Padilha anuncia compra do cabotegravir, PrEP de longa duração
No AIDS 2026, ministro da Saúde tornou pública a aquisição do medicamento de HIV. Também informou sobre o impasse do lenacapavir e um acordo para acompanhar o desenvolvimento do alimatravirhttps://outraspalavras.net/outrasaude/padilha-anuncia-compra-do-cabotegravir-prep-de-longa-duracao/
-
GSK to cut jobs amid £1.9bn cost-cutting plan and bid for faster drug development
By Joanna PartridgePharmaceuticals company is investing £400m in UK life sciences and moving scientists to new Cambridge R&D site
#Pharmaceuticalsindustry #GSK #Business #Biotechnologyindustry #UKnews #Science #Cambridge #Cambridgeshire #Hertfordshire #Stevenage #TheGuardian #JoannaPartridge
-
GSK to cut jobs amid £1.9bn cost-cutting plan and bid for faster drug development
By Joanna PartridgePharmaceuticals company is investing £400m in UK life sciences and moving scientists to new Cambridge R&D site
#Pharmaceuticalsindustry #GSK #Business #Biotechnologyindustry #UKnews #Science #Cambridge #Cambridgeshire #Hertfordshire #Stevenage #TheGuardian #JoannaPartridge
-
GSK to cut jobs amid £1.9bn cost-cutting plan and bid for faster drug development https://www.theguardian.com/business/2026/jul/28/gsk-cut-jobs-cost-cutting-faster-drug-development-cambridge #PharmaceuticalsIndustry #Gsk #Business #BiotechnologyIndustry #UkNews #Science #Cambridge #Cambridgeshire #Hertfordshire #Stevenage
-
GSK to cut jobs amid £1.9bn cost-cutting plan and bid for faster drug development https://www.theguardian.com/business/2026/jul/28/gsk-cut-jobs-cost-cutting-faster-drug-development-cambridge #PharmaceuticalsIndustry #Gsk #Business #BiotechnologyIndustry #UkNews #Science #Cambridge #Cambridgeshire #Hertfordshire #Stevenage
-
GSK to cut jobs amid £1.9bn cost-cutting plan and bid for faster drug development https://www.theguardian.com/business/2026/jul/28/gsk-cut-jobs-cost-cutting-faster-drug-development-cambridge #PharmaceuticalsIndustry #Gsk #Business #BiotechnologyIndustry #UkNews #Science #Cambridge #Cambridgeshire #Hertfordshire #Stevenage
-
GSK to cut jobs amid £1.9bn cost-cutting plan and bid for faster drug development https://www.theguardian.com/business/2026/jul/28/gsk-cut-jobs-cost-cutting-faster-drug-development-cambridge #PharmaceuticalsIndustry #Gsk #Business #BiotechnologyIndustry #UkNews #Science #Cambridge #Cambridgeshire #Hertfordshire #Stevenage
-
GSK купує американську біотех-компанію Nuvalent за $10,6 млрд — це найбільша угода виробника за останні вісім років. Премумія в 40% свідчить про стратегічний розворот назад до онкології після років скорочення цього напряму.
Злиття та поглинання у фармацевтиці — один із ключових індикаторів настроїв у секторі охорони здоров'я. Коли великі гравці платять значну премію за доступ до нових технологій, це часто дає імпульс суміжним компаніям і підвищує увагу до біотех-стартапів на ранніх стадіях.
Для українського інвестора це нагадування: стежте за M&A активністю у фармі та біотеху — вона часто випереджає загальне зростання сектора.
#GSK #MergersAndAcquisitions #Biotech #Онкологія #Інвестиції #Фармацевтика
